RESEARCH USE ONLY · 18+
You must be of legal age in your province and a qualified research professional. All products are for in vitro laboratory research only — not for human or animal consumption.
By entering you confirm you are 18+ and accessing this site in a qualified research capacity. Products are not intended for personal, therapeutic, or clinical use.
You must be 18 years of age or older to enter MGMT Research.
MGMT RESEARCH
Evidence reviewed · October 3, 2026
Retatrutide vs. Semaglutide vs. Tirzepatide — an overview of mechanisms, clinical evidence, and the questions that remain.
Clinical results below concern the medicines and investigational formulations studied in trials. MGMT Research vial images show our laboratory research packaging; those products are separate from branded medicines and trial supplies. Trial outcomes do not establish outcomes for an MGMT Research product.
Single GLP-1 receptor agonism. STEP 1 reported 14.9% mean weight loss at 68 weeks. SELECT demonstrated a 20% relative reduction in major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes. [1] [5]
Dual GIP/GLP-1 receptor agonism. SURMOUNT-1 reported 20.9% at 15 mg using the treatment-regimen estimand, or 22.5% using the efficacy estimand. SURMOUNT-5 directly compared it with Semaglutide: 20.2% versus 13.7% at 72 weeks. [2] [3]
Triple GIP/GLP-1/glucagon receptor agonism. Reported efficacy-estimand results include 28.7% at 68 weeks in TRIUMPH-4 and 28.3% at 80 weeks in TRIUMPH-1. It remains investigational. [6] [7] [14]
Different populations, durations, doses, and statistical approaches can change the result. A larger number from a separate trial is not proof of superiority in a head-to-head comparison.
Single, dual, and triple agonism describe the number of receptor systems engaged. They are useful ways to explain the development of this research family, rather than official “generation” classifications.
GLP-1 receptor activity contributes to glucose-dependent insulin secretion, appetite regulation, and delayed gastric emptying. Semaglutide acts selectively at this receptor.
Tirzepatide and Retatrutide also engage GIPR. Research examines how GIP and GLP-1 activity interact in insulin secretion, adipose metabolism, and energy balance.
Retatrutide adds GCGR activity. Glucagon can increase hepatic glucose production; combined agonism is being studied for effects on energy expenditure and lipid metabolism. Mechanistic explanations remain model-dependent.
Mechanism references: [15] [16]. Weekly injection formulations were used in the trials summarized here; oral Semaglutide formulations also exist. [12]
Tirzepatide is the proper compound name. TIREZ is the name used on our vial packaging.
Tirzepatide product detailsLaboratory research packaging concept.Scroll horizontally to view the full comparison on smaller screens.
| Category | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1R | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| Medicine brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | Investigational; no approved medicine brand |
| Selected weight-loss trial | 14.9% / 68 weeks STEP 1; 2.4 mg [1] | 20.9% / 72 weeks SURMOUNT-1; 15 mg, treatment-regimen estimand 22.5% efficacy estimand [2] | 28.7% / 68 weeks TRIUMPH-4; 12 mg, efficacy estimand 23.7% treatment-regimen estimand [6] |
| Direct comparison / SURMOUNT-5 | 13.7% at 72 weeks | 20.2% at 72 weeks | Not included in SURMOUNT-5 [3] |
| Glucose-control example | A1C −1.86 percentage points in SURPASS-2, 1 mg | A1C −2.30 percentage points in SURPASS-2, 15 mg [4] | A1C −1.5 percentage points at 12 mg in TRIUMPH-2; −1.6 at 9 mg [8] |
| Liver research | 62.9% MASH resolution without worsening fibrosis / ESSENCE | 62% MASH resolution without worsening fibrosis at 15 mg / SYNERGY-NASH | 86% relative liver-fat reduction at 12 mg / Phase 2a Different endpoint [9] [10] [11] |
| Cardiovascular outcomes | SELECT: 20% relative reduction in MACE vs. placebo | SURPASS-CVOT: noninferior to Dulaglutide in type 2 diabetes and established ASCVD | Dedicated outcomes research ongoing; no established cardiovascular event reduction [5] [17] [18] |
| Clinical status | Approved medicines; indications vary by product and jurisdiction | Approved medicines; indications vary by product and jurisdiction | Investigational; Lilly announced a planned Q1 2027 US submission, not an approval date [14] [19] |
Trial doses describe study arms, not dosing instructions. Brand names belong to their respective owners. MGMT Research is not affiliated with those medicine manufacturers.
In 1,961 adults without diabetes, Semaglutide 2.4 mg produced 14.9% mean weight loss versus 2.4% with placebo, alongside lifestyle intervention. [1]
The 15 mg arm produced 20.9% mean weight loss versus 3.1% with placebo using the treatment-regimen estimand. The efficacy estimate was 22.5%; the two figures answer different statistical questions. [2]
Among adults with obesity or overweight and knee osteoarthritis, without diabetes, the 12 mg arm achieved 28.7% using the efficacy estimand. The treatment-regimen estimate was 23.7%. [6]
These are selected trial results, not a three-way head-to-head ranking. An efficacy estimand generally estimates the effect if treatment is taken as planned; a treatment-regimen estimand incorporates treatment discontinuation according to the study’s analysis plan.
At 72 weeks, Tirzepatide produced 6.5 percentage points more mean weight loss than Semaglutide — about 47% more relative to Semaglutide’s result. This does not mean 47 percentage points of weight loss. Retatrutide was not part of this comparison. [3]
The Retatrutide bar shows the separately reported TRIUMPH-4 result, not a SURMOUNT-5 treatment arm. Trial populations, durations and analysis methods differ; these three bars do not establish a three-way head-to-head comparison. [6]
Phase 2 reported 24.2% mean weight loss at 48 weeks with 12 mg. TRIUMPH-1 reported 28.3% at 80 weeks in adults without diabetes; TRIUMPH-2 reported 20.8% at 80 weeks in adults with type 2 diabetes. The Phase 3 figures cited here are efficacy-estimand results. Populations matter. [20] [7] [8]
RETROD is our vial label name for Retatrutide. The clinical evidence in this guide relates to the trial formulations, not our packaging concept.
Retatrutide product detailsLaboratory research packaging concept.MASLD describes metabolic dysfunction-associated steatotic liver disease. MASH includes steatohepatitis, involving inflammation and liver injury. Reducing liver fat on imaging is not the same endpoint as resolving MASH on biopsy.
At 72 weeks, MASH resolution without worsening fibrosis occurred in 62.9% with Semaglutide versus 34.3% with placebo in the reported Phase 3 analysis. [9]
In Phase 2, 62% of the 15 mg group met MASH resolution without worsening fibrosis at 52 weeks, versus 10% with placebo. [10]
At 48 weeks, the 12 mg group showed an 86% mean relative liver-fat reduction; 93% reached liver fat below 5%. These imaging results do not establish MASH resolution or fibrosis improvement. [11]
Glucagon receptor activity provides a biological rationale for studying Retatrutide’s hepatic lipid effects. It does not prove that one receptor alone caused the clinical result, or that Retatrutide is superior to the others for liver outcomes.
SELECT studied Semaglutide in adults with established cardiovascular disease and overweight or obesity, without diabetes. Major cardiovascular events occurred in 6.5% versus 8.0% with placebo: a 20% relative risk reduction, with a 1.5 percentage point difference in observed event proportions. [5]
SURPASS-CVOT studied Tirzepatide against Dulaglutide in adults with type 2 diabetes and atherosclerotic cardiovascular disease and met noninferiority. This active-comparator study answers a different question from SELECT. [17]
Retatrutide’s dedicated TRIUMPH-Outcomes study is evaluating cardiovascular and kidney outcomes. Weight reduction, blood pressure changes, and lipid changes are not proof of fewer heart attacks or strokes. [18]
Nausea, vomiting, diarrhea, and constipation are common in incretin trials, often during dose escalation. Rates from separate trials cannot establish which compound is better tolerated. Formulation, dose, population, and adverse-event collection methods differ.
At 12 mg, nausea was reported in 43.2%, vomiting in 20.9%, and dysesthesia in 20.9% versus 0.7% with placebo for dysesthesia. Dysesthesia refers to altered or unpleasant skin sensations. Adverse-event discontinuation was 18.2% at 12 mg versus 4.0% with placebo. These are TRIUMPH-4-specific observations. [6]
Approved Semaglutide and Tirzepatide labeling includes pancreatitis, gallbladder disease, dehydration-related kidney injury, and thyroid C-cell tumor warnings. These concerns are not unique to only one compound. The human relevance of the rodent thyroid findings is uncertain; a normal thyroid-function panel does not screen for medullary thyroid carcinoma. [12] [13]
Retatrutide remains investigational, with ongoing safety evaluation and no approved prescribing information. Medicine selection and monitoring require a clinician’s assessment of the individual’s history, other medicines, and treatment goals.
There is no universal blood panel or fixed testing schedule required for everyone using an approved weight-management medicine. A clinician selects tests based on diabetes status, kidney and liver disease, symptoms, nutrition, and other medicines.
| Area | Examples | Clinical context |
|---|---|---|
| Blood glucose | HbA1c, glucose | Relevant to diabetes control, hypoglycemia risk, and changes to other diabetes medicines. |
| Kidney function | Creatinine, eGFR, electrolytes | Particularly important with kidney disease or prolonged vomiting, diarrhea, or dehydration. |
| Liver and lipids | ALT, AST, bilirubin; lipid profile | May support evaluation of established liver disease and cardiometabolic risk. Normal liver enzymes do not exclude fatty liver. |
| Nutritional status | Iron studies, B12, folate, vitamin D when indicated | Testing depends on dietary intake, symptoms, and deficiency risk. |
| Thyroid and pancreas | Symptom- and history-directed evaluation | Routine thyroid-function or pancreatic-enzyme panels are not a substitute for evaluating suspected thyroid disease or pancreatitis. |
A blanket baseline / 3-month / 6-month schedule is not established by these trial summaries. Follow the treating clinician’s plan; clinical-trial participants follow the trial’s monitoring protocol. Labeling specifies blood-glucose monitoring in diabetes and renal monitoring when reactions could cause volume depletion. [12] [13]
Semaglutide has a longer clinical history and placebo-controlled cardiovascular outcomes evidence in the SELECT population. Tirzepatide has direct weight-loss superiority evidence over Semaglutide in SURMOUNT-5. Retatrutide has encouraging Phase 3 results, but cross-trial percentages do not settle its comparative benefits or long-term safety.
Lilly announced plans for a US Retatrutide submission in Q1 2027. A submission is not an approval or launch date, and timelines can change. Retatrutide had not been approved by any regulatory agency at this review date. [14] [19]
Peer-reviewed trial publications, manufacturer trial reports, and official medicine labeling. Figures are rounded where indicated.
This comparison is educational and does not provide treatment or dosing advice. MGMT Research products are for laboratory research only, not for human consumption or diagnostic or therapeutic use.